Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vertex Pharmaceuticals Incorporated (VRTX)

301.83   10.52 (3.61%) 07-07 15:04
Open: 292.3 Pre. Close: 291.31
High: 306.08 Low: 291.59
Volume: 1,060,599 Market Cap: 78,258M
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 295.384 - 296.577 296.577 - 297.714
Low: 286.647 - 287.977 287.977 - 289.245
Close: 289.204 - 291.267 291.267 - 293.233

Technical analysis

as of: 2020-07-07 2:40:08 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 357.50     One year: 417.56
Support: Support1: 278.39    Support2: 261.28
Resistance: Resistance1: 306.08    Resistance2: 357.50
Pivot: 288.89
Moving Average: MA(5): 292.06     MA(20): 283.93
MA(100): 257.30     MA(250): 221.96
MACD: MACD(12,26): 5.29     Signal(9): 4.49
Stochastic oscillator: %K(14,3): 81.37     %D(3): 76.09
RSI: RSI(14): 63.44
52-week: High: 306.08  Low: 165.23  Change(%): 68.6
Average Vol(K): 3-Month: 196827  10-Days: 150887

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
VRTX has closed below upper band by 5.3%. Bollinger Bands are 25.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 07 Jul 2020
Is Vertex Pharmaceuticals Incorporated (VRTX) Stock a Good Buy? - InvestorsObserver

Thu, 02 Jul 2020
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

Wed, 01 Jul 2020
Vertex Pharmaceuticals Incorporated (VRTX) Plans and Analysts Expectations - The News Heater

Mon, 29 Jun 2020
Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Thu, 25 Jun 2020
Riding the Trend or Protecting Profits: Vertex Pharmaceuticals Incorporated (VRTX) - The News Heater

Fri, 19 Jun 2020
Vertex Pharmaceuticals Incorporated (VRTX) Rises 5.04% for June 19 -

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 259
Shares Float (M) 259
% Held by Insiders 0.14
% Held by Institutions 97.83
Shares Short (K) 4,210
Shares Short P. Month (K) 3,970

Stock Financials

EPS 5.780
EPS Est This Year 1.630
EPS Est Next Year 2.890
Book Value (p.s.) 24.940
Profit Margin 31.35
Operating Margin 34.17
Return on Assets (ttm) 13.3
Return on Equity (ttm) 27.0
Qtrly Rev. Growth 76.5
Gross Profit (p.s.) 7.174
Sales Per Share 18.590
EBITDA (p.s.) 6.749
Qtrly Earnings Growth 124.40
Operating Cash Flow (M) 2,060
Levered Free Cash Flow (M) 1,330

Stock Valuations

PE Ratio 52.13
PEG Ratio 0.60
Price to Book value 12.08
Price to Sales 16.21
Price to Cash Flow 37.93

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.